Diseases
AAVantgarde Bio Receives FDA Fast Track Designation for AAVB-039 in Stargardt Disease
The US Food and Drug Administration (FDA) has granted Fast Track Designation to AAVantgarde Bio's gene therapy program, AAVB-039, for the treatment of Stargardt disease secondary to biallelic mutation in ABCA4. This designation acknowledges the urgent unmet need and potential of AAVB-039, a therapy that addresses the underlying